A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

This early-phase study is testing a new treatment called AZD0120 for people with multiple myeloma — a type of blood cancer — to see if it is safe and shows early signs of working. **You may be eligible if...** - You are 18 years or older with a confirmed diagnosis of multiple myeloma - You are in good overall health and your organs are functioning well - For newly diagnosed patients: you either haven't started treatment yet, or have completed 4–6 cycles of initial treatment and are considered high-risk - For patients with relapsed or treatment-resistant myeloma: you have received 1 or 2 prior treatments including a proteasome inhibitor and an immunomodulatory drug **You may NOT be eligible if...** - Your overall health score (ECOG) is 2 or higher, meaning significant limitations in daily activity - Your organs (kidneys, liver, bone marrow) are not functioning adequately - You have other serious health conditions that could affect your safety in the study Talk to your doctor to see if this trial is right for you.